Cysteine cathepsins L and X differentially modulate interactions between myeloid-derived suppressor cells and tumor cells.
Cancer
Cathepsin inhibition
Cysteine cathepsins
Immunosuppression
MDA-MB-231 cells
Myeloid-derived suppressor cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
15
02
2020
accepted:
27
04
2020
pubmed:
7
5
2020
medline:
18
8
2020
entrez:
7
5
2020
Statut:
ppublish
Résumé
Increased proteolytic activity of cysteine cathepsins has long been known to facilitate malignant progression, and it has also been associated with tumor-promoting roles of myeloid-derived suppressor cells (MDSCs). Consequently, cysteine cathepsins have gained much attention as potential targets for cancer therapies. However, cross-talk between tumor cells and MDSCs needs to be taken into account when studying the efficacy of cathepsin inhibitors as anti-cancer agents. Here, we demonstrate the potential of the MDA-MB-231 breast cancer cell line to generate functional MDSCs from CD14
Identifiants
pubmed: 32372139
doi: 10.1007/s00262-020-02592-x
pii: 10.1007/s00262-020-02592-x
doi:
Substances chimiques
Cathepsin L
EC 3.4.22.15
Cysteine
K848JZ4886
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1869-1880Subventions
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P4-0127
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : J4-1776
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : J4-8227
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : J4-6811
Références
Groth C, Hu X, Weber R et al (2019) Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer 120:16–25. https://doi.org/10.1038/s41416-018-0333-1
doi: 10.1038/s41416-018-0333-1
pubmed: 30413826
Cassetta L, Baekkevold ES, Brandau S et al (2019) Deciphering myeloid-derived suppressor cells: isolation and markers in humans, mice and non-human primates. Cancer Immunol Immunother 68:687–697. https://doi.org/10.1007/s00262-019-02302-2
doi: 10.1007/s00262-019-02302-2
pubmed: 6447515
pmcid: 6447515
Bruger AM, Dorhoi A, Esendagli G et al (2019) How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother 68:631–644. https://doi.org/10.1007/s00262-018-2170-8
doi: 10.1007/s00262-018-2170-8
pubmed: 29785656
Kochan G (2016) Human MDSCs. In: Escors D, Talmadge JE, Breckpot K, Van Ginderachter JA, Kochan G (eds) Myeloid-derived suppressor cells and cancer. Springer briefs in immunology. Springer, Cham, pp 39–48
doi: 10.1007/978-3-319-26821-7_3
Ostrand-Rosenberg S, Fenselau C (2018) Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment. J Immunol 200:422–431. https://doi.org/10.4049/jimmunol.1701019
doi: 10.4049/jimmunol.1701019
pubmed: 29311384
pmcid: 5765878
Akkari L, Gocheva V, Kester JC et al (2014) Distinct functions of macrophage-derived and cancer cell-derived cathepsin Z combine to promote tumor malignancy via interactions with the extracellular matrix. Genes Dev 28:2134–2150. https://doi.org/10.1101/gad.249599.114
doi: 10.1101/gad.249599.114
pubmed: 25274726
pmcid: 4180975
Edgington-Mitchell LE, Rautela J, Duivenvoorden HM et al (2015) Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer. Oncotarget 6:8–10. https://doi.org/10.18632/oncotarget.4714
doi: 10.18632/oncotarget.4714
Fonović M, Turk B (2014) Cysteine cathepsins and their potential in clinical therapy and biomarker discovery. PROTEOMICS - Clin Appl 8:416–426. https://doi.org/10.1002/prca.201300085
doi: 10.1002/prca.201300085
pubmed: 24470315
Salpeter SJ, Pozniak Y, Merquiol E et al (2015) A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression. Oncogene 34:6066–6078. https://doi.org/10.1038/onc.2015.51
doi: 10.1038/onc.2015.51
pubmed: 25798843
Yang M, Liu J, Shao J et al (2014) Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Mol Cancer 13:43. https://doi.org/10.1186/1476-4598-13-43
doi: 10.1186/1476-4598-13-43
pubmed: 24580730
pmcid: 4015740
Gounaris E, Tung CH, Restaino C et al (2008) Live imaging of cysteine-cathepsin activity reveals dynamics of focal inflammation, angiogenesis, and polyp growth. PLoS ONE 3:e2916. https://doi.org/10.1371/journal.pone.0002916
doi: 10.1371/journal.pone.0002916
pubmed: 18698347
pmcid: 2488397
Bruchard M, Mignot G, Derangère V et al (2013) Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 19:57–64. https://doi.org/10.1038/nm.2999
doi: 10.1038/nm.2999
pubmed: 23202296
Wu QD, Wang JH, Condron C et al (2001) Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 280:C814-22. https://doi.org/10.1152/ajpcell.2001.280.4.C814
doi: 10.1152/ajpcell.2001.280.4.C814
pubmed: 11245598
Fonović UP, Mitrović A, Knez D et al (2017) Identification and characterization of the novel reversible and selective cathepsin X inhibitors. Sci Rep 7:1–11. https://doi.org/10.1038/s41598-017-11935-1
doi: 10.1038/s41598-017-11935-1
Katunuma N, Murata E, Kakegawa H et al (1999) Structure based development of novel specific inhibitors for cathepsin L and cathepsin S in vitro and in vivo. FEBS Lett 458:6–10. https://doi.org/10.1016/S0014-5793(99)01107-2
doi: 10.1016/S0014-5793(99)01107-2
pubmed: 10518923
Mirkovic B, Markelc B, Butinar M et al (2015) Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity. Oncotarget 6:19027–19042. https://doi.org/10.18632/oncotarget.3699
doi: 10.18632/oncotarget.3699
pubmed: 25848918
pmcid: 4662473
Webb SR, Gascoigne NRJ (1994) T-cell activation by superantigens. Curr Opin Immunol 6:467–475. https://doi.org/10.1016/0952-7915(94)90129-5
doi: 10.1016/0952-7915(94)90129-5
pubmed: 7917116
Valiathan R, Lewis JE, Melillo AB et al (2012) Evaluation of a flow cytometry-based assay for natural killer cell activity in clinical settings. Scand J Immunol 75:455–462. https://doi.org/10.1111/j.1365-3083.2011.02667.x
doi: 10.1111/j.1365-3083.2011.02667.x
pubmed: 22150284
Casacuberta-Serra S, Parés M, Golbano A et al (2017) Myeloid-derived suppressor cells can be efficiently generated from human hematopoietic progenitors and peripheral blood monocytes. Immunol Cell Biol 95:538–548. https://doi.org/10.1038/icb.2017.4
doi: 10.1038/icb.2017.4
pubmed: 28108746
Obermajer N, Kalinski P (2012) Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res 1:15. https://doi.org/10.1186/2047-1440-1-15
doi: 10.1186/2047-1440-1-15
pubmed: 23369567
pmcid: 3560989
Heine A, Held SAE, Schulte-Schrepping J et al (2017) Generation and functional characterization of MDSC-like cells. Oncoimmunology 6:e1295203. https://doi.org/10.1080/2162402X.2017.1295203
doi: 10.1080/2162402X.2017.1295203
pubmed: 28507805
pmcid: 5414884
Okada SL, Simmons RM, Franke-Welch S et al (2018) Conditioned media from the renal cell carcinoma cell line 786.O drives human blood monocytes to a monocytic myeloid-derived suppressor cell phenotype. Cell Immunol 323:49–58. https://doi.org/10.1016/j.cellimm.2017.10.014
doi: 10.1016/j.cellimm.2017.10.014
pubmed: 29103587
Lechner MG, Megiel C, Russell SM et al (2011) Functional characterization of human Cd33
doi: 10.1186/1479-5876-9-90
pubmed: 21658270
pmcid: 3128058
Panni RZ, Sanford DE, Belt BA et al (2014) Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Cancer Immunol Immunother 63:513–528. https://doi.org/10.1007/s00262-014-1527-x
doi: 10.1007/s00262-014-1527-x
pubmed: 24652403
pmcid: 3994288
Rodrigues JC, Gonzalez GC, Zhang L et al (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 12:351–365. https://doi.org/10.1093/neuonc/nop023
doi: 10.1093/neuonc/nop023
pubmed: 20308313
Hou L, Cooley J, Swanson R et al (2015) The protease cathepsin L regulates Th17 cell differentiation. J Autoimmun 65:56–63. https://doi.org/10.1016/j.jaut.2015.08.006
doi: 10.1016/j.jaut.2015.08.006
pubmed: 26343333
pmcid: 4679515
Pečar Fonović U (2009) Efficient removal of cathepsin L from active cathepsin X using immunoprecipitation technique. Acta Chim Slov 56:985–988
Greenbaum DC, Arnold WD, Lu F et al (2002) Small molecule affinity fingerprinting. A tool for enzyme family subclassification, target identification, and inhibitor design. Chem Biol 9:1085–1094. https://doi.org/10.1016/s1074-5521(02)00238-7
doi: 10.1016/s1074-5521(02)00238-7
pubmed: 12401493
Jiang M, Chen J, Zhang W et al (2017) Interleukin-6 trans-signaling pathway promotes immunosuppressive myeloid-derived suppressor cells via suppression of suppressor of cytokine signaling 3 in breast cancer. Front Immunol 8:1840. https://doi.org/10.3389/fimmu.2017.01840
doi: 10.3389/fimmu.2017.01840
pubmed: 29326716
pmcid: 5736866
Mao Y, Poschke I, Wennerberg E et al (2013) Melanoma-educated CD14
doi: 10.1158/0008-5472.CAN-12-4115
pubmed: 23633486
Lechner MG, Liebertz DJ, Epstein AL (2010) Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 185:2273–2284. https://doi.org/10.4049/jimmunol.1000901
doi: 10.4049/jimmunol.1000901
pubmed: 20644162
pmcid: 2923483
Elliott LA, Doherty GA, Sheahan K, Ryan EJ (2017) Human tumor-infiltrating myeloid cells: phenotypic and functional diversity. Front Immunol. https://doi.org/10.3389/fimmu.2017.00086
doi: 10.3389/fimmu.2017.00086
pubmed: 28713370
pmcid: 5491541
Movahedi K, Guilliams M, Van den Bossche J et al (2008) Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:4233–4244. https://doi.org/10.1182/blood-2007-07-099226
doi: 10.1182/blood-2007-07-099226
pubmed: 18272812
Idorn M, Kollgaard T, Kongsted P et al (2014) Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 63:1177–1187. https://doi.org/10.1007/s00262-014-1591-2
doi: 10.1007/s00262-014-1591-2
pubmed: 25085000
OuYang L-Y, Wu X-J, Ye S-B et al (2015) Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med 13:47. https://doi.org/10.1186/s12967-015-0410-7
doi: 10.1186/s12967-015-0410-7
pubmed: 25638150
pmcid: 4357065
Chen M-F, Kuan F-C, Yen T-C et al (2014) IL-6-stimulated CD11b
doi: 10.18632/oncotarget.2368
pubmed: 25238263
pmcid: 4226716
Wang Z, Zhang L, Wang H et al (2015) Tumor-induced CD14
doi: 10.1007/s00262-014-1646-4
pubmed: 25548095
Banerjee K, Pru C, Pru JK, Resat H (2018) STAT3 knockdown induces tumor formation by MDA-MB-231 cells. Clin Oncol Res. https://doi.org/10.31487/j.COR.2018.10.002
doi: 10.31487/j.COR.2018.10.002
pubmed: 30234199
pmcid: 6141035
Konjar Š, Sutton VR, Hoves S et al (2010) Human and mouse perforin are processed in part through cleavage by the lysosomal cysteine proteinase cathepsin L. Immunology 131:257–267. https://doi.org/10.1111/j.1365-2567.2010.03299.x
doi: 10.1111/j.1365-2567.2010.03299.x
pubmed: 20497254
pmcid: 2967271
Yan X, Wu C, Chen T et al (2017) Cathepsin S inhibition changes regulatory T-cell activity in regulating bladder cancer and immune cell proliferation and apoptosis. Mol Immunol 82:66–74. https://doi.org/10.1016/j.molimm.2016.12.018
doi: 10.1016/j.molimm.2016.12.018
pubmed: 28033540